Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
News|Articles|October 3, 2024
Concurrent Chemoradiation/Atezolizumab Does Not Improve Survival in LS-SCLC
Author(s)Russ Conroy
Fact checked by: Gina Mauro
Data show that twice-daily radiotherapy may confer improved survival vs once-daily radiation in patients with limited-stage small cell lung cancer.
Advertisement
Advertisement
The addition of atezolizumab (Tecentriq) to concurrent chemoradiotherapy (CRT) did not improve survival outcomes among patients with limited-stage small cell lung cancer (LS-SCLC), according to findings from the phase 3 NRG-LU005 trial (NCT03811002) presented at the
Related to this article
Data presented at WCLC 2026 support the use of B7-H3–directed antibody-drug conjugates and brain MRI surveillance in small cell lung cancer.
The phase 3 EXCALIBER-RRMM trial supports iberdomide plus daratumumab and dexamethasone as a new standard of care in relapsed/refractory multiple myeloma.
C. Ola Landgren, MD, PhD, discusses disparities in myeloma care access between academic and community practices and how his center works to bridge that gap.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
No new safety signals were observed with the daratumumab regimen after an additional 3 years of follow-up in the phase 3 PERSEUS study.
Ethan B. Ludmir, MD, discussed neoadjuvant radiation, advanced treatment techniques, the HYPERION CCA trial, and lirafugratinib in cholangiocarcinoma.
In the phase 3 CERVINO trial, etentamig showed an early overall survival signal in patients with triple-class exposed relapsed/refractory multiple myeloma.
Advertisement
Advertisement